News

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1…

2 years ago

Osteal Therapeutics Closes $23M Series C Financing

Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM…

2 years ago

Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million

NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY,…

2 years ago

Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ETISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) --…

2 years ago

Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross

SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on…

2 years ago

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration…

2 years ago

Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104

The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b trial in EoENEW ORLEANS and…

2 years ago

electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference

ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced…

2 years ago

NeurAxis Reports Second Quarter 2023 Financial Results

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company…

2 years ago

Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM

Bionano original equipment manufacturing (OEM) partner Ecobono obtained reagent Class I registration and approval for Bionano’s DNA isolation kits for…

2 years ago